RNA Aptamers Targeting Integrin α5β1 as Probes for Cyto- and Histofluorescence in Glioblastoma.
Fiche publication
Date publication
mai 2019
Journal
Molecular therapy. Nucleic acids
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHOULIER Laurence, Dr DONTENWILL Monique, Dr ETIENNE-SELLOUM Nelly, Dr GUENOT Dominique, Pr LEHMANN Maxime, Dr MARTIN Sophie
Tous les auteurs :
Fechter P, Cruz Da Silva E, Mercier MC, Noulet F, Etienne-Seloum N, Guenot D, Lehmann M, Vauchelles R, Martin S, Lelong-Rebel I, Ray AM, Seguin C, Dontenwill M, Choulier L
Lien Pubmed
Résumé
Nucleic acid aptamers are often referred to as chemical antibodies. Because they possess several advantages, like their smaller size, temperature stability, ease of chemical modification, lack of immunogenicity and toxicity, and lower cost of production, aptamers are promising tools for clinical applications. Aptamers against cell surface protein biomarkers are of particular interest for cancer diagnosis and targeted therapy. In this study, we identified and characterized RNA aptamers targeting cells expressing integrin α5β1. This αβ heterodimeric cell surface receptor is implicated in tumor angiogenesis and solid tumor aggressiveness. In glioblastoma, integrin α5β1 expression is associated with an aggressive phenotype and a decrease in patient survival. We used a complex and original hybrid SELEX (selective evolution of ligands by exponential enrichment) strategy combining protein-SELEX cycles on the recombinant α5β1 protein, surrounded by cell-SELEX cycles using two different cell lines. We identified aptamer H02, able to differentiate, in cyto- and histofluorescence assays, glioblastoma cell lines, and tissues from patient-derived tumor xenografts according to their α5 expression levels. Aptamer H02 is therefore an interesting tool for glioblastoma tumor characterization.
Mots clés
SELEX, aptahistofluorescence, aptamer, cell-surface biomarker, cytofluorescence, glioblastoma, integrin α5β1, therapeutic payloads delivery
Référence
Mol Ther Nucleic Acids. 2019 May 24;17:63-77